GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q3 FY26 results · Oct–Dec 2025
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹1,041.26 crore (up 9.7% from Q3 FY25) and net profit of ₹295.62 crore (up 28.6% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,041.26 | 949.42 | +9.7% | 979.94 | +6.3% |
| Other income | 32.12 | 35.07 | −8.4% | 33.57 | −4.3% |
| Total income | 1,073.38 | 984.49 | +9.0% | 1,013.51 | +5.9% |
| Profit before tax | 399.93 | 308.10 | +29.8% | 354.00 | +13.0% |
| Net profit for the period | 295.62 | 229.88 | +28.6% | 257.49 | +14.8% |
| EPS, basic (₹) | 16.54 | 13.57 | +21.9% | 15.07 | +9.8% |
| Net margin (%) | 28.4 | 24.2 | 26.3 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,022.59 | 946.36 | +8.1% | 973.63 | +5.0% |
| Other income | 31.82 | 35.06 | −9.2% | 31.27 | +1.8% |
| Total income | 1,054.41 | 981.42 | +7.4% | 1,004.90 | +4.9% |
| Profit before tax | 377.89 | 306.35 | +23.4% | 350.65 | +7.8% |
| Net profit for the period | 277.18 | 228.58 | +21.3% | 255.00 | +8.7% |
| EPS, basic (₹) | 16.36 | 13.49 | +21.3% | 14.92 | +9.7% |
| Net margin (%) | 27.1 | 24.2 | 26.2 |
Consolidated
- Filed with BSE
- 09 Feb 2026, 19:20 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2026, 19:20 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE